Human trials could start soon on Adam’s 3D printed bone grafts

By

Adam — a young company with technology to 3D print bone grafts made out of ceramic bioglass and modified biopolymer — said today that it expects first human trials to start by the end of the year.

Officials at the Groton, Conn.– and Odessa, Ukraine–based company expect preclinical trials to finish this month. The Adam technology uses Kwambio printers and reduces the standard production cost of synthetic bones in half, from $0.12–$0.15/cm2 down to just $0.08.

Ideally, the bone graft dissolves as new bone grows, reducing the need for additional surgery, according to Adam.

If you want to read more about this news, click here. 

 

Posted in News, Science, Technology.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    10 octubre, 2019

    Deep brain stimulation can be effective for severe depression

    Researchers who monitored people with deep brain stimulation implants for 8 years suggest that the treatment can benefit those with severe depression. Regulators in the United States have already approved deep brain stimulation for the treatment of Parkinson’s disease, epilepsy, essential tremor, and obsessive-compulsive disorder. The treatment involves implanting wires into the brain and a stimulator in the chest …

  •
    10 octubre, 2019

    Medtronic announces Infuse spine trial

    Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures. The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, …

  •
    24 agosto, 2020

    COFEPRIS Evolves

  •
    18 junio, 2019

    More than 1 million Class I medical device units recalled in Q1

    For the third consecutive quarter, more than one million Class I units were recalled during 2019’s Q1. If you want to read more about this news click here. If you want to read more about this news click here.